Day: November 13, 2024

Preliminary third quarter 2024 revenue to be approximately $113 million* Q3 materials grew 10% year-over-year and 9% sequentially, offset by declines in printer revenues driven by continued macro-related pressures on capital spending* Record year of product innovation and regulatory approvals supporting future growth in key markets such as Dental, Personalized Healthcare, Aerospace & Defense. This positions the company for exciting future revenue growth as the economy normalizes Management expects to release and discuss complete third quarter 2024 results the week of November 25, 2024*The preliminary financial data above and below remains subject to the company’s close process. Accordingly, actual results may differ from the anticipated results shown. ROCK HILL, S.C., Nov. 13, 2024 (GLOBE NEWSWIRE) — 3D Systems (NYSE:DDD)...

Company achieves positive Adjusted EBITDA* for the third consecutive quarter, reaching $0.9 million year-to-date, a $4.3 million improvement year-on-year Third-quarter operating expenses reduced by 44% year-on-year with year-to-date operating expenses down by 38% Existing debt obligation maturity extended to January 2027BOCA RATON, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) — SpringBig Holdings, Inc. (“Springbig” or the “Company”) (OTCQX: SBIG), a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs, today announced its financial results for the third quarter ended September 30, 2024, and amendments to the terms of its debt obligations. “We are reporting a third quarter of positive Adjusted EBITDA*, and our eighth consecutive quarter of improving Adjusted EBITDA*. Our...

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.0 million, or $0.33 per diluted share, on net sales of $33.2 million for the first quarter of fiscal year 2025 compared to a net loss of $0.7 million, or $0.12 per diluted share, in the first quarter of the prior fiscal year. Net sales during the three months ended September 30, 2024, decreased $0.8 million, or 2.4%, to $33.2 million as compared to $34.0 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales decreased $1.6 million, a 4.8% decrease from the comparable quarter last year. Private-label contract manufacturing...

MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol ‘TLX’. The Company continues to have its primary listing on ASX, with the Nasdaq listing of ADSs expected to complement the Company’s ASX listing. Each ADS represents one fully paid ordinary share of the Company. Telix has not issued any new shares as part of the Nasdaq listing. Initial trading of ADSs may be limited as existing shareholders take time to transition their TLX shares to ADSs. JPMorgan Chase Bank. N.A. has been appointed as the depositary, custodian and registrar for the ADS program. Dr. Christian Behrenbruch, Managing Director and Group Chief Executive...